Two Final Events Hold the Key for Sellas Life Sciences as the Stock Races Ahead of Its Fundamentals

Sellas Life Sciences has turned into a live referendum on a single clinical dataset, with the stock’s eye-popping 594% annual gain reflecting little more than a probabilistic wager on two outstanding data points. The Nasdaq-listed biotech, traded in Frankfurt, closed on Friday at €12.85 after a modest 1.91% dip — a rare retreat in a chart that has otherwise shot nearly vertical. Over the past 30 days alone, the shares have surged 81.5%, pushing annualized volatility to a staggering 124% and leaving traditional valuation metrics far behind.

The binary bet centres on the phase 3 REGAL trial, which is testing galinpepimut-S against acute myeloid leukaemia. Management reported in late June that 78 of the 80 required patient events had been recorded. The final two events remain pending, and the company has not set a date for the next update. Chief executive Ulrich Dauer has interpreted the delay positively, suggesting that treated patients are living longer. But the market is pricing in that scenario well before the data are formally unblinded and verified.

That disconnect is visible across every technical indicator. The relative strength index sits at 72, firmly in overbought territory. The stock is trading roughly 83% above its 50-day moving average and an astonishing 245% above its 200-day average — gaps that historically tend to close. Since hitting a 52-week high of €15.25 at the end of June, the shares have already given back about 16%. That pullback followed a 951% rally from the November 2025 low, a classic consolidation pattern after an explosive move.

Analyst consensus tells a similar story of stretched expectations. The average price target stands at €8.74, implying downside of around 32% from current levels. Against a market capitalisation of €2.57 billion, the gap between fundamental models and market pricing could hardly be wider. The company has no approved product on the market, yet retail investors have piled in with conviction, encouraged by a low free float and a platform that recently assigned an 83% probability to a successful study readout by November.

Should investors sell immediately? Or is it worth buying Sellas Life Sciences?

Bullish traders see the delayed events as a clear signal of efficacy. If the final analysis confirms a statistically significant survival benefit, they expect the stock to retest the June high of €15.25. The company is well capitalised for that scenario: it held roughly $107 million in cash at the end of March, supplemented by a further $29 million from exercised warrants. That war chest would be enough to fund a regulatory submission. A secondary catalyst also looms in late 2026, when phase 2 data for the second candidate SLS009 are expected.

On the bearish side, even a marginal survival advantage could prove insufficient to justify the current valuation. The speculative capital that has driven the stock to a €2.57 billion market cap could evaporate quickly if the REGAL trial misses its primary endpoint. Short-term positioning may also add to the volatility: with the stock technically overbought and the analyst target indicating a 32% downside, the risk of a hard reset is elevated. The 50-day moving average near €7.03 and the analyst target of €8.74 represent potential support levels in a pullback.

For now, the market remains in wait-and-watch mode. Every additional data point on the trial’s progress will move the stock. The next major trigger will come only when Sellas announces the 80th event, triggering the unblinded analysis. Until then, the shares are trading as a proxy for a single probabilistic outcome — a rare moment where the binary nature of a clinical trial is fully priced in real time, with no room for gradual fundamental adjustment.